PPD Announces 2011 PPD Beach2Battleship Triathlon Heroes
October 13 2011 - 2:11PM
Business Wire
PPD, Inc. (Nasdaq: PPDI) today announced the 2011 PPD Heroes
team, featuring cancer survivors and medical specialists competing
as triathletes in the PPD Beach2Battleship Triathlon on Oct. 29.
The PPD Heroes are helping raise public awareness about the value
of participating in clinical trials in the development of
life-changing medicines.
For people facing illness, participating in a clinical trial can
offer new opportunities for cutting-edge treatment and close
medical supervision. Increasing the number of patients who
participate in clinical trials can help accelerate research into
new medical treatments.
“We are proud to sponsor this premier triathlon, and we are
pleased to introduce the 2011 team of PPD Heroes,” said Ray Hill,
CEO of PPD. “We look forward to welcoming them to Wilmington, home
of PPD’s global headquarters, and cheering them on during race day.
They are an inspiration to us all.”
The 2011 team of PPD Heroes includes:
- Kristen Adelman, a four-time
non-Hodgkin’s lymphoma survivor who participated in a clinical
trial that she says saved her life. “The care I received was the
absolute best,” she said, “and the team of doctors and nurses was
incredible.”
- Claudio Battaglini, Ph.D., a professor
conducting research on the effects of exercise training in
mitigating side effects of anti-cancer treatments. “Without
clinical trials,” he said, “it is virtually impossible to test new
interventions to improve the quality of our lives.”
- Wendy Chioji, who was diagnosed with
stage II breast cancer and participated in a clinical trial in part
to help reduce the suffering of others in the future. “Before I
even knew if I would get better,” she said, “participating in a
clinical trial was a way for me to pay it forward.”
- Roseann Dougherty, who at age 10 lost
her mother to brain cancer and went on to become an oncology nurse
and start a nonprofit organization to provide healing resources for
cancer patients. “Clinical trials can provide hope and new
treatments,” she said.
- Mary Kreis, Ph.D., who learned she was
pregnant and had melanoma during a cross-country bike ride. Through
a clinical trial, she underwent surgeries during her pregnancy and
gave birth to a healthy baby girl named Viva to symbolize living
life to the fullest. “Without clinical trials,” Kreis said, “my
cancer may have been missed."
The PPD Beach2Battleship Triathlon has been ranked one of the
top five triathlons in the world by Triathlete magazine.
Approximately 1,875 triathletes from 43 U.S. states and five other
nations are converging in Wilmington and Wrightsville Beach, N.C.,
for the event. It is expected to generate approximately $3.9
million in local economic impact. Funds raised from the event will
benefit the Wilmington Family YMCA.
The iron distance triathlon includes a 2.4-mile swim, a 112-mile
bike ride and a 26.2-mile run, and the event also offers a
half-triathlon course. The race starts in Wrightsville Beach, winds
through New Hanover, Pender, Sampson and Bladen counties and ends
at the USS North Carolina Battleship Memorial in downtown
Wilmington.
PPD is a leading global contract research organization providing
drug discovery, development and lifecycle management services. Our
clients and partners include pharmaceutical, biotechnology, medical
device, academic and government organizations. With offices in 44
countries and more than 11,000 professionals worldwide, PPD applies
innovative technologies, therapeutic expertise and a commitment to
quality to help clients and partners accelerate the delivery of
safe and effective therapeutics and maximize the returns on their
R&D investments. For more information, visit www.ppdi.com.
Except for historical information, all of the statements,
expectations and assumptions, including statements, expectations
and assumptions about the PPD Beach2Battleship Triathlon events,
contained in this news release are forward-looking statements that
involve a number of risks and uncertainties. Although PPD attempts
to be accurate in making these forward-looking statements, it is
possible that future circumstances might differ from the
assumptions on which such statements are based and could cause
actual results to differ materially from the forward-looking
statements. Other important factors which could cause future
results to differ materially include the following: overall global
economic conditions; economic conditions in the pharmaceutical,
biotechnology and government-sponsored research sectors; research
and development spending in the pharmaceutical, biotechnology and
government-sponsored research sectors; outsourcing trends in the
pharmaceutical, biotechnology and government-sponsored research
sectors; consolidation in pharmaceutical and biotechnology
industries; competition in the outsourcing industry; PPD’s ability
to win new business; loss, delay or modification of large
contracts; higher-than-expected cancellation rates; the rate of
conversion of backlog into revenue; actual operating performance;
fluctuations in currency exchange rates; the ability to attract,
integrate and retain key personnel; risks associated with and
dependence on strategic relationships; risks associated with
acquisitions and investments, such as impairments and integration,
including PPD’s investment in Celtic Therapeutics; rapid
technological advances that make our services less competitive;
risks associated with fixed price contracts and cost overruns;
compliance with drug development regulations; changes in the
regulation of the drug development process; international economic
and political risks; risks that we may increase, reduce or
discontinue our annual dividend policy; and the ability to control
SG&A spending. These and other PPD risk factors are set forth
in more detail from time to time in our SEC filings, copies of
which are available free of charge upon request from PPD’s investor
relations department. PPD assumes no obligation and expressly
disclaims any duty to update these forward-looking statements in
the future, except as required by applicable law. These
forward-looking statements should not be relied upon as
representing PPD’s estimates or views as of any date subsequent to
the date hereof.
Pharmaceutical Product Developme (NASDAQ:PPDI)
Historical Stock Chart
From Aug 2024 to Sep 2024
Pharmaceutical Product Developme (NASDAQ:PPDI)
Historical Stock Chart
From Sep 2023 to Sep 2024